ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 147,16
-0,33%
Dow Jones
43 006,59
1,14%
DAX
23 158,20
0,17%
Brent Oil
69,465
0,29%
Bitcoin
90 898,09
0,29%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Nuvectis Pharma Inc (NVCT)

  7. Nuvectis Pharma Inc (NVCT) Actualités

NVCT

Nuvectis Pharma (NVCT)

Nuvectis Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NVCT
DateHeureSourceTitreSymboleSociété
27/02/202516h43Business WireMarket News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital MarketsNASDAQ:NVCTNuvectis Pharma Inc
25/02/202522h05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NVCTNuvectis Pharma Inc
25/02/202515h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NVCTNuvectis Pharma Inc
06/02/202512h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NVCTNuvectis Pharma Inc
04/01/202500h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NVCTNuvectis Pharma Inc
03/01/202523h00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NVCTNuvectis Pharma Inc
05/11/202414h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NVCTNuvectis Pharma Inc
28/10/202413h21Business WirePESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data UpdateNASDAQ:NVCTNuvectis Pharma Inc
16/09/202413h15Business WirePESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to WatchNASDAQ:NVCTNuvectis Pharma Inc
27/06/202314h46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NVCTNuvectis Pharma Inc
16/06/202322h46Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NVCTNuvectis Pharma Inc
10/05/202322h31Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NVCTNuvectis Pharma Inc
28/04/202322h08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NVCTNuvectis Pharma Inc
03/04/202314h16Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:NVCTNuvectis Pharma Inc
30/03/202312h09Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:NVCTNuvectis Pharma Inc
27/03/202314h31Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:NVCTNuvectis Pharma Inc
17/03/202321h32Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:NVCTNuvectis Pharma Inc
08/03/202323h32Edgar (US Regulatory)Annual Report (10-k)NASDAQ:NVCTNuvectis Pharma Inc
09/01/202316h19Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NVCTNuvectis Pharma Inc
14/09/202212h15TipRanksH.C. Wainwright Reaffirms Their Buy Rating on Nuvectis Pharma (NVCT)NASDAQ:NVCTNuvectis Pharma Inc
15/08/202215h10Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:NVCTNuvectis Pharma Inc
10/08/202222h31Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:NVCTNuvectis Pharma Inc
05/08/202216h45TipRanksH.C. Wainwright Sticks to Its Buy Rating for Nuvectis Pharma (NVCT)NASDAQ:NVCTNuvectis Pharma Inc
21/06/202215h56TipRanksNuvectis Pharma (NVCT) Receives a Buy from H.C. WainwrightNASDAQ:NVCTNuvectis Pharma Inc
11/04/202218h25TipRanksAnalysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS) and Nuvectis Pharma (NVCT)NASDAQ:NVCTNuvectis Pharma Inc
05/04/202212h16TipRanksH.C. Wainwright Keeps Their Buy Rating on Nuvectis Pharma (NVCT)NASDAQ:NVCTNuvectis Pharma Inc
28/03/202223h23Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:NVCTNuvectis Pharma Inc
24/03/202218h16Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NVCTNuvectis Pharma Inc
24/03/202213h11Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:NVCTNuvectis Pharma Inc
22/03/202215h55TipRanksH.C. Wainwright Reiterates Their Buy Rating on Nuvectis Pharma (NVCT)NASDAQ:NVCTNuvectis Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:NVCT

Dernières Valeurs Consultées

SPI
SP500
S&P 500
NASDAQ
MSFT
Microsoft
COIN
XRPUSD
Ripple
FTSE
UKX
FTSE 100
COIN
BTCUSD
Bitcoin
EU
PX1
CAC 40
EU
CAP
Capgemini
EU
MC
Lvmh Moet Hennessy Louis...
EU
HO
Thales
EU
EN
Bouygues
NYSE
JPM
JP Morgan Chase
EU
LR
Legrand
NYSE
KO
Coca Cola
NYSE
DIS
Walt Disney
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces